{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:30:36Z","timestamp":1792690236107,"version":"4.5.0"},"reference-count":265,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41571-026-01148-9","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:00:00Z","timestamp":1776078000000},"page":"539-556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multidisciplinary management of meningiomas in the era of precision oncology"],"prefix":"10.1038","volume":"23","author":[{"given":"Majid","family":"Assadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6294-8118","authenticated-orcid":false,"given":"Malik E.","family":"Juweid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Lohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Minniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-1962","authenticated-orcid":false,"given":"Felix","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Ivanidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Karschnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Landry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7212-6521","authenticated-orcid":false,"given":"Felix M.","family":"Mottaghy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gelareh","family":"Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"1148_CR1","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3171\/2015.4.JNS142742","volume":"124","author":"DJ Englot","year":"2016","unstructured":"Englot, D. J. et al. Seizures in supratentorial meningioma: a systematic review and meta-analysis. J. Neurosurg. 124, 1552\u20131561 (2016).","journal-title":"J. Neurosurg."},{"key":"1148_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1212\/WNL.54.1.71","volume":"54","author":"J Antinheimo","year":"2000","unstructured":"Antinheimo, J. et al. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 54, 71\u201376 (2000).","journal-title":"Neurology"},{"key":"1148_CR3","doi-asserted-by":"publisher","DOI":"10.3171\/FOC-07\/10\/E2","volume":"23","author":"JS Barnholtz-Sloan","year":"2007","unstructured":"Barnholtz-Sloan, J. S. & Kruchko, C. Meningiomas: causes and risk factors. Neurosurg. Focus 23, E2 (2007).","journal-title":"Neurosurg. Focus"},{"key":"1148_CR4","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/1078-0432.CCR-0938-3","volume":"10","author":"B Asgharian","year":"2004","unstructured":"Asgharian, B. et al. Meningiomas may be a component tumor of multiple endocrine neoplasia type 1. Clin. Cancer Res. 10, 869\u2013880 (2004).","journal-title":"Clin. Cancer Res."},{"key":"1148_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.18632\/oncoscience.305","volume":"3","author":"E Yakubov","year":"2016","unstructured":"Yakubov, E. et al. Hidden association of Cowden syndrome, PTEN mutation and meningioma frequency. Oncoscience 3, 149\u2013155 (2016).","journal-title":"Oncoscience"},{"key":"1148_CR6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/neuros\/nyy121","volume":"83","author":"K Kerr","year":"2018","unstructured":"Kerr, K., Qualmann, K., Esquenazi, Y., Hagan, J. & Kim, D. H. Familial syndromes involving meningiomas provide mechanistic insight into sporadic disease. Neurosurgery 83, 1107\u20131118 (2018).","journal-title":"Neurosurgery"},{"key":"1148_CR7","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3171\/2011.6.JNS11129","volume":"115","author":"EB Claus","year":"2011","unstructured":"Claus, E. B. et al. Family and personal medical history and risk of meningioma. J. Neurosurg. 115, 1072\u20131077 (2011).","journal-title":"J. Neurosurg."},{"key":"1148_CR8","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1212\/WNL.0000000000002020","volume":"85","author":"T Niedermaier","year":"2015","unstructured":"Niedermaier, T. et al. Body mass index, physical activity, and risk of adult meningioma and glioma: a meta-analysis. Neurology 85, 1342\u20131350 (2015).","journal-title":"Neurology"},{"key":"1148_CR9","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/cncr.10410","volume":"94","author":"BS Custer","year":"2002","unstructured":"Custer, B. S., Koepsell, T. D. & Mueller, B. A. The association between breast carcinoma and meningioma in women. Cancer 94, 1626\u20131635 (2002).","journal-title":"Cancer"},{"key":"1148_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078078","volume":"384","author":"N Roland","year":"2024","unstructured":"Roland, N. et al. Use of progestogens and the risk of intracranial meningioma: national case-control study. BMJ 384, e078078 (2024).","journal-title":"BMJ"},{"key":"1148_CR11","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"1148_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/neuonc\/noae170","volume":"27","author":"F Sahm","year":"2025","unstructured":"Sahm, F. et al. cIMPACT-NOW update 8: clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas. Neuro Oncol. 27, 319\u2013330 (2025).","journal-title":"Neuro Oncol."},{"key":"1148_CR13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1001\/jamaoncol.2025.0329","volume":"11","author":"AP Landry","year":"2025","unstructured":"Landry, A. P. et al. Chromosome 1p Loss and 1q gain for grading of meningioma. JAMA Oncol. 11, 644\u2013649 (2025).","journal-title":"JAMA Oncol."},{"key":"1148_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/neuonc\/noae198","volume":"27","author":"MP Nguyen","year":"2025","unstructured":"Nguyen, M. P. et al. A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence. Neuro Oncol. 27, 445\u2013454 (2025).","journal-title":"Neuro Oncol."},{"key":"1148_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","volume":"597","author":"F Nassiri","year":"2021","unstructured":"Nassiri, F. et al. A clinically applicable integrative molecular classification of meningiomas. Nature 597, 119\u2013125 (2021).","journal-title":"Nature"},{"key":"1148_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","volume":"140","author":"P Sievers","year":"2020","unstructured":"Sievers, P. et al. CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol. 140, 409\u2013413 (2020).","journal-title":"Acta Neuropathol."},{"key":"1148_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9030319","volume":"9","author":"C Ogasawara","year":"2021","unstructured":"Ogasawara, C., Philbrick, B. D. & Adamson, D. C. Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions. Biomedicines 9, 319 (2021).","journal-title":"Biomedicines"},{"key":"1148_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4132\/jptm.2019.11.05","volume":"54","author":"YS Lee","year":"2020","unstructured":"Lee, Y. S. & Lee, Y. S. Molecular characteristics of meningiomas. J. Pathol. Transl. Med. 54, 45\u201363 (2020).","journal-title":"J. Pathol. Transl. Med."},{"key":"1148_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-020-01084-w","volume":"20","author":"PD Delgado-Lopez","year":"2020","unstructured":"Delgado-Lopez, P. D., Cubo-Delgado, E., Gonzalez-Bernal, J. J. & Martin-Alonso, J. A practical overview on the molecular biology of meningioma. Curr. Neurol. Neurosci. Rep. 20, 62 (2020).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"1148_CR20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","volume":"18","author":"F Sahm","year":"2017","unstructured":"Sahm, F. et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 18, 682\u2013694 (2017).","journal-title":"Lancet Oncol."},{"key":"1148_CR21","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/neuonc\/noz061","volume":"21","author":"F Nassiri","year":"2019","unstructured":"Nassiri, F. et al. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro Oncol. 21, 901\u2013910 (2019).","journal-title":"Neuro Oncol."},{"key":"1148_CR22","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/neuonc\/noy104","volume":"20","author":"S Spiegl-Kreinecker","year":"2018","unstructured":"Spiegl-Kreinecker, S. et al. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro Oncol. 20, 1584\u20131593 (2018).","journal-title":"Neuro Oncol."},{"key":"1148_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1648953","volume":"15","author":"RH Ali","year":"2025","unstructured":"Ali, R. H. et al. Molecular and histopathological landscape of 131 meningiomas: a retrospective institutional study with insights from cIMPACT-NOW. Front. Oncol. 15, 1648953 (2025).","journal-title":"Front. Oncol."},{"key":"1148_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/363515a0","volume":"363","author":"GA Rouleau","year":"1993","unstructured":"Rouleau, G. A. et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363, 515\u2013521 (1993).","journal-title":"Nature"},{"key":"1148_CR25","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","volume":"72","author":"JA Trofatter","year":"1993","unstructured":"Trofatter, J. A. et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72, 791\u2013800 (1993).","journal-title":"Cell"},{"key":"1148_CR26","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","volume":"373","author":"AR Asthagiri","year":"2009","unstructured":"Asthagiri, A. R. et al. Neurofibromatosis type 2. Lancet 373, 1974\u20131986 (2009).","journal-title":"Lancet"},{"key":"1148_CR27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng0294-180","volume":"6","author":"MH Ruttledge","year":"1994","unstructured":"Ruttledge, M. H. et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat. Genet. 6, 180\u2013184 (1994).","journal-title":"Nat. Genet."},{"key":"1148_CR28","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.1158\/1078-0432.CCR-10-0891","volume":"16","author":"S Goutagny","year":"2010","unstructured":"Goutagny, S. et al. Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin. Cancer Res. 16, 4155\u20134164 (2010).","journal-title":"Clin. Cancer Res."},{"key":"1148_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2017.168","volume":"14","author":"M Preusser","year":"2018","unstructured":"Preusser, M., Brastianos, P. K. & Mawrin, C. Advances in meningioma genetics: novel therapeutic opportunities. Nat. Rev. Neurol. 14, 106\u2013115 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"1148_CR30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1093\/neuonc\/noaa226","volume":"23","author":"MW Youngblood","year":"2021","unstructured":"Youngblood, M. W. et al. Associations of meningioma molecular subgroup and tumor recurrence. Neuro Oncol. 23, 783\u2013794 (2021).","journal-title":"Neuro Oncol."},{"key":"1148_CR31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/neuonc\/nov316","volume":"18","author":"M Abedalthagafi","year":"2016","unstructured":"Abedalthagafi, M. et al. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 18, 649\u2013655 (2016).","journal-title":"Neuro Oncol."},{"key":"1148_CR32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/neuonc\/now029","volume":"18","author":"G Zadeh","year":"2016","unstructured":"Zadeh, G., Karimi, S. & Aldape, K. D. PIK3CA mutations in meningioma. Neuro Oncol. 18, 603\u2013604 (2016).","journal-title":"Neuro Oncol."},{"key":"1148_CR33","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","volume":"339","author":"VE Clark","year":"2013","unstructured":"Clark, V. E. et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339, 1077\u20131080 (2013).","journal-title":"Science"},{"key":"1148_CR34","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00401-013-1195-5","volume":"126","author":"C Koelsche","year":"2013","unstructured":"Koelsche, C. et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 126, 907\u2013915 (2013).","journal-title":"Acta Neuropathol."},{"key":"1148_CR35","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/jmg.2009.075721","volume":"47","author":"KD Hadfield","year":"2010","unstructured":"Hadfield, K. D., Smith, M. J., Trump, D., Newman, W. G. & Evans, D. G. SMARCB1 mutations are not a common cause of multiple meningiomas. J. Med. Genet. 47, 567\u2013568 (2010).","journal-title":"J. Med. Genet."},{"key":"1148_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10048-011-0300-y","volume":"13","author":"P van den Munckhof","year":"2012","unstructured":"van den Munckhof, P., Christiaans, I., Kenter, S. B., Baas, F. & Hulsebos, T. J. Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. Neurogenetics 13, 1\u20137 (2012).","journal-title":"Neurogenetics"},{"key":"1148_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.721712","volume":"11","author":"RN Prasad","year":"2021","unstructured":"Prasad, R. N. et al. Germline BAP1 mutation in a family with multi-generational meningioma with rhabdoid features: a case series and literature review. Front. Oncol. 11, 721712 (2021).","journal-title":"Front. Oncol."},{"key":"1148_CR38","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1093\/neuonc\/nox094","volume":"19","author":"GM Shankar","year":"2017","unstructured":"Shankar, G. M. & Santagata, S. BAP1 mutations in high-grade meningioma: implications for patient care. Neuro Oncol. 19, 1447\u20131456 (2017).","journal-title":"Neuro Oncol."},{"key":"1148_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/ng.2526","volume":"45","author":"PK Brastianos","year":"2013","unstructured":"Brastianos, P. K. et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat. Genet. 45, 285\u2013289 (2013).","journal-title":"Nat. Genet."},{"key":"1148_CR40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cancergen.2015.02.003","volume":"208","author":"MJ Smith","year":"2015","unstructured":"Smith, M. J. Germline and somatic mutations in meningiomas. Cancer Genet. 208, 107\u2013114 (2015).","journal-title":"Cancer Genet."},{"key":"1148_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12970","volume":"32","author":"AS Berghoff","year":"2022","unstructured":"Berghoff, A. S. et al. Prognostic impact of genetic alterations and methylation classes in meningioma. Brain Pathol. 32, e12970 (2022).","journal-title":"Brain Pathol."},{"key":"1148_CR42","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(06)70625-1","volume":"5","author":"MJ Riemenschneider","year":"2006","unstructured":"Riemenschneider, M. J., Perry, A. & Reifenberger, G. Histological classification and molecular genetics of meningiomas. Lancet Neurol. 5, 1045\u20131054 (2006).","journal-title":"Lancet Neurol."},{"key":"1148_CR43","doi-asserted-by":"publisher","DOI":"10.3892\/br.2025.1934","volume":"22","author":"EK Dwianingsih","year":"2025","unstructured":"Dwianingsih, E. K., Krisnugraha, Y. P., Bawono, R. G. & Malueka, R. G. Molecular biomarkers in meningioma (Review). Biomed. Rep. 22, 56 (2025).","journal-title":"Biomed. Rep."},{"key":"1148_CR44","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/path.4427","volume":"234","author":"MJ Smith","year":"2014","unstructured":"Smith, M. J. et al. Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas. J. Pathol. 234, 436\u2013440 (2014).","journal-title":"J. Pathol."},{"key":"1148_CR45","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bpa.12524","volume":"28","author":"A Tauziede-Espariat","year":"2018","unstructured":"Tauziede-Espariat, A. et al. Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: a comprehensive immunophenotypical and molecular analysis. Brain Pathol. 28, 466\u2013474 (2018).","journal-title":"Brain Pathol."},{"key":"1148_CR46","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00401-020-02247-2","volume":"141","author":"P Sievers","year":"2021","unstructured":"Sievers, P. et al. Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. Acta Neuropathol. 141, 281\u2013290 (2021).","journal-title":"Acta Neuropathol."},{"key":"1148_CR47","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm.3947","volume":"21","author":"LM LaFave","year":"2015","unstructured":"LaFave, L. M. et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat. Med. 21, 1344\u20131349 (2015).","journal-title":"Nat. Med."},{"key":"1148_CR48","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41388-020-01568-6","volume":"40","author":"DM Fountain","year":"2021","unstructured":"Fountain, D. M. et al. The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges. Oncogene 40, 875\u2013884 (2021).","journal-title":"Oncogene"},{"key":"1148_CR49","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00401-023-02635-4","volume":"146","author":"J Boetto","year":"2023","unstructured":"Boetto, J. et al. Normal meninges harbor oncogenic somatic mutations in meningioma-driver genes. Acta Neuropathol. 146, 833\u2013835 (2023).","journal-title":"Acta Neuropathol."},{"key":"1148_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091753","volume":"16","author":"SJ Trybula","year":"2024","unstructured":"Trybula, S. J. et al. The evolving classification of meningiomas: integration of molecular discoveries to inform patient care. Cancers 16, 1753 (2024).","journal-title":"Cancers"},{"key":"1148_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15225339","volume":"15","author":"R Halabi","year":"2023","unstructured":"Halabi, R. et al. Unveiling a biomarker signature of meningioma: the need for a panel of genomic, epigenetic, proteomic, and RNA biomarkers to advance diagnosis and prognosis. Cancers 15, 5339 (2023).","journal-title":"Cancers"},{"key":"1148_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60653-0","volume":"16","author":"JY Lee","year":"2025","unstructured":"Lee, J. Y. et al. Single-cell analysis reveals a longitudinal trajectory of meningioma evolution and heterogeneity. Nat. Commun. 16, 5481 (2025).","journal-title":"Nat. Commun."},{"key":"1148_CR53","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","volume":"54","author":"A Choudhury","year":"2022","unstructured":"Choudhury, A. et al. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat. Genet. 54, 649\u2013659 (2022).","journal-title":"Nat. Genet."},{"key":"1148_CR54","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1038\/s41591-023-02586-z","volume":"29","author":"WC Chen","year":"2023","unstructured":"Chen, W. C. et al. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat. Med. 29, 3067\u20133076 (2023).","journal-title":"Nat. Med."},{"key":"1148_CR55","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1038\/s41591-024-03167-4","volume":"30","author":"JZ Wang","year":"2024","unstructured":"Wang, J. Z. et al. Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma. Nat. Med. 30, 3173\u20133183 (2024).","journal-title":"Nat. Med."},{"key":"1148_CR56","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.wneu.2024.03.051","volume":"186","author":"T Han","year":"2024","unstructured":"Han, T., Liu, X. & Zhou, J. Progression\/recurrence of meningioma: an imaging review based on magnetic resonance imaging. World Neurosurg. 186, 98\u2013107 (2024).","journal-title":"World Neurosurg."},{"key":"1148_CR57","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/neuonc\/nov247","volume":"18","author":"CL Rogers","year":"2016","unstructured":"Rogers, C. L. et al. Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neuro Oncol. 18, 565\u2013574 (2016).","journal-title":"Neuro Oncol."},{"key":"1148_CR58","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1136\/jnnp-2019-322257","volume":"91","author":"C Mirian","year":"2020","unstructured":"Mirian, C. et al. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis. J. Neurol. Neurosurg. Psychiatry 91, 378\u2013387 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1148_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv377","volume":"108","author":"F Sahm","year":"2016","unstructured":"Sahm, F. et al. TERT promoter mutations and risk of recurrence in meningioma. J. Natl Cancer Inst. 108, djv377 (2016).","journal-title":"J. Natl Cancer Inst."},{"key":"1148_CR60","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1038\/onc.2012.436","volume":"32","author":"M Peyre","year":"2013","unstructured":"Peyre, M. et al. Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation. Oncogene 32, 4264\u20134272 (2013).","journal-title":"Oncogene"},{"key":"1148_CR61","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S1470-2045(25)00422-X","volume":"26","author":"KJ Groff","year":"2025","unstructured":"Groff, K. J. et al. The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis. Lancet Oncol. 26, 1178\u20131190 (2025).","journal-title":"Lancet Oncol."},{"key":"1148_CR62","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S1470-2045(25)00267-0","volume":"26","author":"C Gui","year":"2025","unstructured":"Gui, C. et al. Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study. Lancet Oncol. 26, 1191\u20131203 (2025).","journal-title":"Lancet Oncol."},{"key":"1148_CR63","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00401-023-02571-3","volume":"146","author":"JZ Wang","year":"2023","unstructured":"Wang, J. Z. et al. Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas. Acta Neuropathol. 146, 145\u2013162 (2023).","journal-title":"Acta Neuropathol."},{"key":"1148_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-017-0014-7","volume":"2","author":"WL Bi","year":"2017","unstructured":"Bi, W. L. et al. Genomic landscape of high-grade meningiomas. NPJ Genom. Med. 2, 15 (2017).","journal-title":"NPJ Genom. Med."},{"key":"1148_CR65","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1750-3639.2009.00356.x","volume":"20","author":"Y Lee","year":"2010","unstructured":"Lee, Y. et al. Genomic landscape of meningiomas. Brain Pathol. 20, 751\u2013762 (2010).","journal-title":"Brain Pathol."},{"key":"1148_CR66","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3171\/2015.6.JNS15591","volume":"125","author":"WL Bi","year":"2016","unstructured":"Bi, W. L. et al. Genomic landscape of intracranial meningiomas. J. Neurosurg. 125, 525\u2013535 (2016).","journal-title":"J. Neurosurg."},{"key":"1148_CR67","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1093\/neuonc\/noae082","volume":"26","author":"JZ Wang","year":"2024","unstructured":"Wang, J. Z. et al. Meningioma: international consortium on meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients. Neuro Oncol. 26, 1742\u20131780 (2024).","journal-title":"Neuro Oncol."},{"key":"1148_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.910199","volume":"12","author":"EJ Wang","year":"2022","unstructured":"Wang, E. J. et al. Recent advances in the molecular prognostication of meningiomas. Front. Oncol. 12, 910199 (2022).","journal-title":"Front. Oncol."},{"key":"1148_CR69","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/neuonc\/noab213","volume":"24","author":"J Driver","year":"2022","unstructured":"Driver, J. et al. A molecularly integrated grade for meningioma. Neuro Oncol. 24, 796\u2013808 (2022).","journal-title":"Neuro Oncol."},{"key":"1148_CR70","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1200\/JCO.21.00784","volume":"39","author":"SLN Maas","year":"2021","unstructured":"Maas, S. L. N. et al. Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated. J. Clin. Oncol. 39, 3839\u20133852 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1148_CR71","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.wneu.2018.08.019","volume":"119","author":"DT Proctor","year":"2018","unstructured":"Proctor, D. T., Ramachandran, S., Lama, S. & Sutherland, G. R. Towards molecular classification of meningioma: evolving treatment and diagnostic paradigms. World Neurosurg. 119, 366\u2013373 (2018).","journal-title":"World Neurosurg."},{"key":"1148_CR72","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00401-017-1678-x","volume":"133","author":"A Olar","year":"2017","unstructured":"Olar, A. et al. Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathol. 133, 431\u2013444 (2017).","journal-title":"Acta Neuropathol."},{"key":"1148_CR73","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/neuonc\/noae242","volume":"27","author":"AP Landry","year":"2025","unstructured":"Landry, A. P. et al. Development and validation of a molecular classifier of meningiomas. Neuro Oncol. 27, 1258\u20131269 (2025).","journal-title":"Neuro Oncol."},{"key":"1148_CR74","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/neuonc\/noac224","volume":"25","author":"A Choudhury","year":"2023","unstructured":"Choudhury, A. et al. Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Neuro Oncol. 25, 520\u2013530 (2023).","journal-title":"Neuro Oncol."},{"key":"1148_CR75","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm6247","volume":"8","author":"JC Bayley","year":"2022","unstructured":"Bayley, J. C. et al. Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies. Sci. Adv. 8, eabm6247 (2022).","journal-title":"Sci. Adv."},{"key":"1148_CR76","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/neuonc\/noae236","volume":"27","author":"AP Landry","year":"2025","unstructured":"Landry, A. P. et al. Validation and next-generation update of a DNA methylation-based recurrence predictor for meningioma: a multicenter prospective study. Neuro Oncol. 27, 1004\u20131016 (2025).","journal-title":"Neuro Oncol."},{"key":"1148_CR77","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/s41591-024-02995-8","volume":"30","author":"DT Hoang","year":"2024","unstructured":"Hoang, D. T. et al. Prediction of DNA methylation-based tumor types from histopathology in central nervous system tumors with deep learning. Nat. Med. 30, 1952\u20131961 (2024).","journal-title":"Nat. Med."},{"key":"1148_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-023-01707-6","volume":"12","author":"H Gu","year":"2024","unstructured":"Gu, H. et al. Enhancing mitosis quantification and detection in meningiomas with computational digital pathology. Acta Neuropathol. Commun. 12, 7 (2024).","journal-title":"Acta Neuropathol. Commun."},{"key":"1148_CR79","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.crad.2006.09.009","volume":"62","author":"S O\u2019Leary","year":"2007","unstructured":"O\u2019Leary, S., Adams, W. M., Parrish, R. W. & Mukonoweshuro, W. Atypical imaging appearances of intracranial meningiomas. Clin. Radiol. 62, 10\u201317 (2007).","journal-title":"Clin. Radiol."},{"key":"1148_CR80","doi-asserted-by":"publisher","DOI":"10.1177\/20584601211009472","volume":"10","author":"E Matsusue","year":"2021","unstructured":"Matsusue, E. et al. Utility of 3T single-voxel proton MR spectroscopy for differentiating intracranial meningiomas from intracranial enhanced mass lesions. Acta Radiol. Open. 10, 20584601211009472 (2021).","journal-title":"Acta Radiol. Open."},{"key":"1148_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116975","volume":"415","author":"HJ Meyer","year":"2020","unstructured":"Meyer, H. J., Wienke, A. & Surov, A. ADC values of benign and high grade meningiomas and associations with tumor cellularity and proliferation \u2014 a systematic review and meta-analysis. J. Neurol. Sci. 415, 116975 (2020).","journal-title":"J. Neurol. Sci."},{"key":"1148_CR82","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s13760-022-02169-8","volume":"123","author":"FA De Stefano","year":"2023","unstructured":"De Stefano, F. A. et al. Unique magnetic resonance spectroscopy profile of intracranial meningiomas compared to gliomas: a systematic review. Acta Neurol. Belg. 123, 2077\u20132084 (2023).","journal-title":"Acta Neurol. Belg."},{"key":"1148_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207612","volume":"13","author":"MC Lin","year":"2018","unstructured":"Lin, M. C. et al. Preoperative grading of intracranial meningioma by magnetic resonance spectroscopy (1H-MRS). PLoS ONE 13, e0207612 (2018).","journal-title":"PLoS ONE"},{"key":"1148_CR84","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.3171\/2019.3.FOCUS1954","volume":"46","author":"S Chidambaram","year":"2019","unstructured":"Chidambaram, S. et al. Dynamic contrast-enhanced magnetic resonance imaging perfusion characteristics in meningiomas treated with resection and adjuvant radiosurgery. Neurosurg. Focus 46, E10 (2019).","journal-title":"Neurosurg. Focus"},{"key":"1148_CR85","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s11060-010-0445-9","volume":"103","author":"A Zimny","year":"2011","unstructured":"Zimny, A. & Sasiadek, M. Contribution of perfusion-weighted magnetic resonance imaging in the differentiation of meningiomas and other extra-axial tumors: case reports and literature review. J. Neurooncol. 103, 777\u2013783 (2011).","journal-title":"J. Neurooncol."},{"key":"1148_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2019.105643","volume":"190","author":"T Siempis","year":"2020","unstructured":"Siempis, T. et al. Diagnostic performance of diffusion and perfusion MRI in differentiating high from low-grade meningiomas: a systematic review and meta-analysis. Clin. Neurol. Neurosurg. 190, 105643 (2020).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"1148_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-78311-8","volume":"14","author":"M Karabacak","year":"2024","unstructured":"Karabacak, M., Patil, S., Feng, R., Shrivastava, R. K. & Margetis, K. A large scale multi institutional study for radiomics driven machine learning for meningioma grading. Sci. Rep. 14, 26191 (2024).","journal-title":"Sci. Rep."},{"key":"1148_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204161","volume":"13","author":"ED Gennatas","year":"2018","unstructured":"Gennatas, E. D. et al. Preoperative and postoperative prediction of long-term meningioma outcomes. PLoS ONE 13, e0204161 (2018).","journal-title":"PLoS ONE"},{"key":"1148_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1536751","volume":"16","author":"P Noori Mirtaheri","year":"2025","unstructured":"Noori Mirtaheri, P. et al. Performance of deep learning models for automatic histopathological grading of meningiomas: a systematic review and meta-analysis. Front. Neurol. 16, 1536751 (2025).","journal-title":"Front. Neurol."},{"key":"1148_CR90","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11060-023-04511-3","volume":"166","author":"L Ren","year":"2024","unstructured":"Ren, L. et al. The development of a combined clinico-radiomics model for predicting post-operative recurrence in atypical meningiomas: a multicenter study. J. Neurooncol. 166, 59\u201371 (2024).","journal-title":"J. Neurooncol."},{"key":"1148_CR91","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11060-022-04063-y","volume":"159","author":"H Speckter","year":"2022","unstructured":"Speckter, H. et al. MRI radiomics in the prediction of the volumetric response in meningiomas after gamma knife radiosurgery. J. Neurooncol. 159, 281\u2013291 (2022).","journal-title":"J. Neurooncol."},{"key":"1148_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174415","volume":"15","author":"BH Akkurt","year":"2023","unstructured":"Akkurt, B. H. et al. Radiomics-based prediction of TERT promotor mutations in intracranial high-grade meningiomas. Cancers 15, 4415 (2023).","journal-title":"Cancers"},{"key":"1148_CR93","doi-asserted-by":"publisher","first-page":"e752","DOI":"10.1016\/j.crad.2023.06.006","volume":"78","author":"C Duan","year":"2023","unstructured":"Duan, C. et al. Prediction of progesterone receptor expression in high-grade meningioma by using radiomics based on enhanced T1WI. Clin. Radiol. 78, e752\u2013e757 (2023).","journal-title":"Clin. Radiol."},{"key":"1148_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1138069","volume":"13","author":"CM Moon","year":"2023","unstructured":"Moon, C. M. et al. Preoperative prediction of Ki-67 and p53 status in meningioma using a multiparametric MRI-based clinical-radiomic model. Front. Oncol. 13, 1138069 (2023).","journal-title":"Front. Oncol."},{"key":"1148_CR95","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/neuonc\/noad028","volume":"25","author":"RV Patel","year":"2023","unstructured":"Patel, R. V., Yao, S., Huang, R. Y. & Bi, W. L. Application of radiomics to meningiomas: a systematic review. Neuro Oncol. 25, 1166\u20131176 (2023).","journal-title":"Neuro Oncol."},{"key":"1148_CR96","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11060-010-0367-6","volume":"99","author":"D Saloner","year":"2010","unstructured":"Saloner, D., Uzelac, A., Hetts, S., Martin, A. & Dillon, W. Modern meningioma imaging techniques. J. Neurooncol. 99, 333\u2013340 (2010).","journal-title":"J. Neurooncol."},{"key":"1148_CR97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163554","volume":"11","author":"MA Lum","year":"2016","unstructured":"Lum, M. A. et al. Intra-arterial MR perfusion imaging of meningiomas: comparison to digital subtraction angiography and intravenous MR perfusion imaging. PLoS ONE 11, e0163554 (2016).","journal-title":"PLoS ONE"},{"key":"1148_CR98","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/RCT.0b013e3180ca9565","volume":"32","author":"J Zhen","year":"2008","unstructured":"Zhen, J. et al. Preoperative evaluation of venous systems with computed tomography venography in parasagittal meningiomas. J. Comput. Assist. Tomogr. 32, 293\u2013297 (2008).","journal-title":"J. Comput. Assist. Tomogr."},{"key":"1148_CR99","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1007\/s00330-005-2788-8","volume":"15","author":"A Bozzao","year":"2005","unstructured":"Bozzao, A. et al. Role of contrast-enhanced MR venography in the preoperative evaluation of parasagittal meningiomas. Eur. Radiol. 15, 1790\u20131796 (2005).","journal-title":"Eur. Radiol."},{"key":"1148_CR100","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/jon.12632","volume":"29","author":"J Ivanidze","year":"2019","unstructured":"Ivanidze, J. et al. Gallium-68 DOTATATE PET in the evaluation of intracranial meningiomas. J. Neuroimaging 29, 650\u2013656 (2019).","journal-title":"J. Neuroimaging"},{"key":"1148_CR101","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/neuros\/nyaa333","volume":"88","author":"M Ueberschaer","year":"2020","unstructured":"Ueberschaer, M. et al. Simpson grade revisited \u2014 intraoperative estimation of the extent of resection in meningiomas versus postoperative somatostatin receptor positron emission tomography\/computed tomography and magnetic resonance imaging. Neurosurgery 88, 140\u2013146 (2020).","journal-title":"Neurosurgery"},{"key":"1148_CR102","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1093\/neuonc\/nox112","volume":"19","author":"N Galldiks","year":"2017","unstructured":"Galldiks, N. et al. PET imaging in patients with meningioma \u2014 report of the RANO\/PET Group. Neuro Oncol. 19, 1576\u20131587 (2017).","journal-title":"Neuro Oncol."},{"key":"1148_CR103","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00259-012-2155-3","volume":"39","author":"A Afshar-Oromieh","year":"2012","unstructured":"Afshar-Oromieh, A. et al. Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET\/CT and contrast-enhanced MRI. Eur. J. Nucl. Med. Mol. Imaging 39, 1409\u20131415 (2012).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1148_CR104","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1007\/s00259-024-06783-x","volume":"51","author":"NL Albert","year":"2024","unstructured":"Albert, N. L. et al. Joint EANM\/EANO\/RANO\/SNMMI practice guideline\/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0. Eur. J. Nucl. Med. Mol. Imaging 51, 3662\u20133679 (2024).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1148_CR105","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1016\/j.jacr.2025.02.036","volume":"22","author":"J Ivanidze","year":"2025","unstructured":"Ivanidze, J. et al. ACR Appropriateness Criteria(R) brain tumors. J. Am. Coll. Radiol. 22, S108\u2013S135 (2025).","journal-title":"J. Am. Coll. Radiol."},{"key":"1148_CR106","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<620::AID-IJC2>3.0.CO;2-S","volume":"76","author":"A Dutour","year":"1998","unstructured":"Dutour, A. et al. Expression of somatostatin receptor subtypes in human brain tumors. Int. J. Cancer 76, 620\u2013627 (1998).","journal-title":"Int. J. Cancer"},{"key":"1148_CR107","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2967\/jnumed.125.270115","volume":"66","author":"R Ebner","year":"2025","unstructured":"Ebner, R. et al. Retrospective evaluation of the correlation between somatostatin receptor PET\/CT and histopathology in patients with suspected intracranial meningiomas. J. Nucl. Med. 66, 1561\u20131567 (2025).","journal-title":"J. Nucl. Med."},{"key":"1148_CR108","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2967\/jnumed.114.149120","volume":"56","author":"W Rachinger","year":"2015","unstructured":"Rachinger, W. et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J. Nucl. Med. 56, 347\u2013353 (2015).","journal-title":"J. Nucl. Med."},{"key":"1148_CR109","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.2967\/jnumed.117.191932","volume":"58","author":"WG Kunz","year":"2017","unstructured":"Kunz, W. G. et al. Improved detection of transosseous meningiomas using 68Ga-DOTATATE PET\/CT compared with contrast-enhanced MRI. J. Nucl. Med. 58, 1580\u20131587 (2017).","journal-title":"J. Nucl. Med."},{"key":"1148_CR110","volume":"3","author":"SS Mahase","year":"2021","unstructured":"Mahase, S. S. et al. [(68)Ga]-DOTATATE PET\/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas. Neurooncol. Adv. 3, vdab012 (2021).","journal-title":"Neurooncol. Adv."},{"key":"1148_CR111","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.210067","volume":"4","author":"J Ivanidze","year":"2022","unstructured":"Ivanidze, J. et al. Dynamic 68Ga-DOTATATE PET\/MRI in the diagnosis and management of intracranial meningiomas. Radiol. Imaging Cancer 4, e210067 (2022).","journal-title":"Radiol. Imaging Cancer"},{"key":"1148_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13467-9","volume":"12","author":"SH Kim","year":"2022","unstructured":"Kim, S. H. et al. Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [68Ga]-DOTATATE PET\/MRI analysis in patients with meningioma. Sci. Rep. 12, 9256 (2022).","journal-title":"Sci. Rep."},{"key":"1148_CR113","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/neuonc\/noae067","volume":"26","author":"J Ivanidze","year":"2024","unstructured":"Ivanidze, J. et al. [Ga68] DOTATATE PET\/MRI-guided radiosurgical treatment planning and response assessment in meningiomas. Neuro Oncol. 26, 1526\u20131535 (2024).","journal-title":"Neuro Oncol."},{"key":"1148_CR114","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.2967\/jnumed.110.074773","volume":"51","author":"A Boss","year":"2010","unstructured":"Boss, A. et al. Hybrid PET\/MRI of intracranial masses: initial experiences and comparison to PET\/CT. J. Nucl. Med. 51, 1198\u20131205 (2010).","journal-title":"J. Nucl. Med."},{"key":"1148_CR115","doi-asserted-by":"publisher","first-page":"7958","DOI":"10.1021\/ac0512599","volume":"77","author":"S Koljenovic","year":"2005","unstructured":"Koljenovic, S., Schut, T. B., Vincent, A., Kros, J. M. & Puppels, G. J. Detection of meningioma in dura mater by Raman spectroscopy. Anal. Chem. 77, 7958\u20137965 (2005).","journal-title":"Anal. Chem."},{"key":"1148_CR116","doi-asserted-by":"publisher","DOI":"10.3171\/CASE24867","volume":"9","author":"J Ivanidze","year":"2025","unstructured":"Ivanidze, J. et al. Preoperative PET\/MRI and radio-guided surgery using [Cu64]DOTATATE in meningioma: a feasibility study. Illustrative case. J. Neurosurg. Case Lessons 9, CASE24867 (2025).","journal-title":"J. Neurosurg. Case Lessons"},{"key":"1148_CR117","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.wneu.2017.01.070","volume":"101","author":"RA Kessler","year":"2017","unstructured":"Kessler, R. A. et al. Metastatic atypical and anaplastic meningioma: a case series and review of the literature. World Neurosurg. 101, 47\u201356 (2017).","journal-title":"World Neurosurg."},{"key":"1148_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.820287","volume":"11","author":"M Roytman","year":"2021","unstructured":"Roytman, M. et al. PET\/MR imaging of somatostatin receptor expression and tumor vascularity in meningioma: implications for pathophysiology and tumor outcomes. Front. Oncol. 11, 820287 (2021).","journal-title":"Front. Oncol."},{"key":"1148_CR119","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3174\/ajnr.A8219","volume":"45","author":"JT Kim","year":"2024","unstructured":"Kim, J. T. et al. DOTATATE PET\/MR imaging differentiates secondary-progressive from de novo World Health Organization grade 3 meningiomas. AJNR Am. J. Neuroradiol. 45, 773\u2013780 (2024).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"1148_CR120","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/neuonc\/noae253","volume":"27","author":"F Sahm","year":"2025","unstructured":"Sahm, F. et al. European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection. Neuro Oncol. 27, 869\u2013883 (2025).","journal-title":"Neuro Oncol."},{"key":"1148_CR121","unstructured":"National Comprehensive Cancer Network. Central Nervous System Cancers Version 2.2025 (NCCN, 2025)."},{"key":"1148_CR122","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s002590050034","volume":"27","author":"JC Reubi","year":"2000","unstructured":"Reubi, J. C. et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 27, 273\u2013282 (2000).","journal-title":"Eur. J. Nucl. Med."},{"key":"1148_CR123","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2967\/jnumed.110.084236","volume":"52","author":"HR Maecke","year":"2011","unstructured":"Maecke, H. R. & Reubi, J. C. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J. Nucl. Med. 52, 841\u2013844 (2011).","journal-title":"J. Nucl. Med."},{"key":"1148_CR124","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1007\/s00259-003-1255-5","volume":"30","author":"D Wild","year":"2003","unstructured":"Wild, D. et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur. J. Nucl. Med. Mol. Imaging 30, 1338\u20131347 (2003).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1148_CR125","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.wneu.2017.08.060","volume":"107","author":"EJ Lee","year":"2017","unstructured":"Lee, E. J., Park, J. H., Park, E. S. & Kim, J. H. \u201cWait-and-see\u201d strategies for newly diagnosed intracranial meningiomas based on the risk of future observation failure. World Neurosurg. 107, 604\u2013611 (2017).","journal-title":"World Neurosurg."},{"key":"1148_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01523","volume":"10","author":"L Zhao","year":"2020","unstructured":"Zhao, L. et al. An overview of managements in meningiomas. Front. Oncol. 10, 1523 (2020).","journal-title":"Front. Oncol."},{"key":"1148_CR127","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","volume":"23","author":"R Goldbrunner","year":"2021","unstructured":"Goldbrunner, R. et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 23, 1821\u20131834 (2021).","journal-title":"Neuro Oncol."},{"key":"1148_CR128","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11060-019-03104-3","volume":"142","author":"AI Islim","year":"2019","unstructured":"Islim, A. I. et al. Incidental intracranial meningiomas: a systematic review and meta-analysis of prognostic factors and outcomes. J. Neurooncol. 142, 211\u2013221 (2019).","journal-title":"J. Neurooncol."},{"key":"1148_CR129","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s11060-021-03832-5","volume":"154","author":"H Ahmeti","year":"2021","unstructured":"Ahmeti, H. et al. Risks and neurological benefits of meningioma surgery in elderly patients compared to young patients. J. Neurooncol. 154, 335\u2013344 (2021).","journal-title":"J. Neurooncol."},{"key":"1148_CR130","first-page":"579","volume":"17","author":"T Kaley","year":"2019","unstructured":"Kaley, T. & Nabors, L. B. Management of central nervous system tumors. J. Natl Compr. Canc. Netw. 17, 579\u2013582 (2019).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"1148_CR131","doi-asserted-by":"publisher","first-page":"E14","DOI":"10.3171\/2015.9.FOCUS15339","volume":"39","author":"P Ferroli","year":"2015","unstructured":"Ferroli, P. et al. Predicting functional impairment in brain tumor surgery: the big five and the Milan complexity scale. Neurosurg. Focus 39, E14 (2015).","journal-title":"Neurosurg. Focus"},{"key":"1148_CR132","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3171\/2015.9.JNS15754","volume":"125","author":"K Gousias","year":"2016","unstructured":"Gousias, K., Schramm, J. & Simon, M. The Simpson grading revisited: aggressive surgery and its place in modern meningioma management. J. Neurosurg. 125, 551\u2013560 (2016).","journal-title":"J. Neurosurg."},{"key":"1148_CR133","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3171\/2010.3.JNS091971","volume":"113","author":"ME Sughrue","year":"2010","unstructured":"Sughrue, M. E. et al. The relevance of Simpson grade I and II resection in modern neurosurgical treatment of World Health Organization grade I meningiomas. J. Neurosurg. 113, 1029\u20131035 (2010).","journal-title":"J. Neurosurg."},{"key":"1148_CR134","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3171\/2020.6.JNS201904","volume":"135","author":"TH Schwartz","year":"2021","unstructured":"Schwartz, T. H. & McDermott, M. W. The Simpson grade: abandon the scale but preserve the message. J. Neurosurg. 135, 488\u2013495 (2021).","journal-title":"J. Neurosurg."},{"key":"1148_CR135","first-page":"478","volume":"12","author":"B Owusu-Adjei","year":"2025","unstructured":"Owusu-Adjei, B. et al. An evidence-based framework for postoperative surveillance of meningioma. Neurooncol. Pract. 12, 478\u2013488 (2025).","journal-title":"Neurooncol. Pract."},{"key":"1148_CR136","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s00259-023-06400-3","volume":"51","author":"N Teske","year":"2023","unstructured":"Teske, N. et al. Postoperative [68Ga]Ga-DOTA-TATE PET\/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1. Eur. J. Nucl. Med. Mol. Imaging 51, 206\u2013217 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1148_CR137","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3171\/2019.9.JNS192075","volume":"134","author":"DG Eichberg","year":"2021","unstructured":"Eichberg, D. G. et al. Stimulated Raman histology for rapid and accurate intraoperative diagnosis of CNS tumors: prospective blinded study. J. Neurosurg. 134, 137\u2013143 (2021).","journal-title":"J. Neurosurg."},{"key":"1148_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02977-7","volume":"11","author":"F Jelke","year":"2021","unstructured":"Jelke, F. et al. Intraoperative discrimination of native meningioma and dura mater by Raman spectroscopy. Sci. Rep. 11, 23583 (2021).","journal-title":"Sci. Rep."},{"key":"1148_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100219","volume":"36","author":"M Movahed-Ezazi","year":"2023","unstructured":"Movahed-Ezazi, M. et al. Clinical validation of stimulated Raman histology for rapid intraoperative diagnosis of central nervous system tumors. Mod. Pathol. 36, 100219 (2023).","journal-title":"Mod. Pathol."},{"key":"1148_CR140","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41591-019-0715-9","volume":"26","author":"TC Hollon","year":"2020","unstructured":"Hollon, T. C. et al. Near real-time intraoperative brain tumor diagnosis using stimulated Raman histology and deep neural networks. Nat. Med. 26, 52\u201358 (2020).","journal-title":"Nat. Med."},{"key":"1148_CR141","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41586-024-08169-3","volume":"637","author":"A Kondepudi","year":"2025","unstructured":"Kondepudi, A. et al. Foundation models for fast, label-free detection of glioma infiltration. Nature 637, 439\u2013445 (2025).","journal-title":"Nature"},{"key":"1148_CR142","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00401-022-02415-6","volume":"143","author":"A Patel","year":"2022","unstructured":"Patel, A. et al. Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study. Acta Neuropathol. 143, 609\u2013612 (2022).","journal-title":"Acta Neuropathol."},{"key":"1148_CR143","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41591-025-03562-5","volume":"31","author":"A Patel","year":"2025","unstructured":"Patel, A. et al. Prospective, multicenter validation of a platform for rapid molecular profiling of central nervous system tumors. Nat. Med. 31, 1567\u20131577 (2025).","journal-title":"Nat. Med."},{"key":"1148_CR144","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-025-01427-7","volume":"17","author":"FE Emiliani","year":"2025","unstructured":"Emiliani, F. E. et al. Nanopore-based random genomic sampling for intraoperative molecular diagnosis. Genome Med. 17, 6 (2025).","journal-title":"Genome Med."},{"key":"1148_CR145","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s10143-020-01428-7","volume":"44","author":"F Behling","year":"2021","unstructured":"Behling, F. et al. The role of Simpson grading in meningiomas after integration of the updated WHO classification and adjuvant radiotherapy. Neurosurg. Rev. 44, 2329\u20132336 (2021).","journal-title":"Neurosurg. Rev."},{"key":"1148_CR146","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1227\/NEU.0b013e31822d408a","volume":"70","author":"A Santacroce","year":"2012","unstructured":"Santacroce, A. et al. Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients. Neurosurgery 70, 32\u201339 (2012).","journal-title":"Neurosurgery"},{"key":"1148_CR147","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.3171\/2019.3.FOCUS1970","volume":"46","author":"N Fatima","year":"2019","unstructured":"Fatima, N., Meola, A., Pollom, E. L., Soltys, S. G. & Chang, S. D. Stereotactic radiosurgery versus stereotactic radiotherapy in the management of intracranial meningiomas: a systematic review and meta-analysis. Neurosurg. Focus 46, E2 (2019).","journal-title":"Neurosurg. Focus"},{"key":"1148_CR148","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1007\/s10143-022-01806-3","volume":"45","author":"L Vagnoni","year":"2022","unstructured":"Vagnoni, L. et al. Radiation therapy for atypical and anaplastic meningiomas: an overview of current results and controversial issues. Neurosurg. Rev. 45, 3019\u20133033 (2022).","journal-title":"Neurosurg. Rev."},{"key":"1148_CR149","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.radonc.2020.11.014","volume":"156","author":"SE Combs","year":"2021","unstructured":"Combs, S. E. et al. ESTRO ACROP guideline for target volume delineation of skull base tumors. Radiother. Oncol. 156, 80\u201394 (2021).","journal-title":"Radiother. Oncol."},{"key":"1148_CR150","first-page":"i67","volume":"5","author":"WC Chen","year":"2023","unstructured":"Chen, W. C., Lucas, C. G., Magill, S. T., Rogers, C. L. & Raleigh, D. R. Radiotherapy and radiosurgery for meningiomas. Neurooncol. Adv. 5, i67\u2013i83 (2023).","journal-title":"Neurooncol. Adv."},{"key":"1148_CR151","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jocn.2020.11.033","volume":"83","author":"A Bush","year":"2021","unstructured":"Bush, A. et al. Mask-based immobilization in Gamma Knife stereotactic radiosurgery. J. Clin. Neurosci. 83, 37\u201342 (2021).","journal-title":"J. Clin. Neurosci."},{"key":"1148_CR152","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.21873\/anticanres.12954","volume":"38","author":"C Scaringi","year":"2018","unstructured":"Scaringi, C., Agolli, L. & Minniti, G. Technical advances in radiation therapy for brain tumors. Anticancer Res. 38, 6041\u20136045 (2018).","journal-title":"Anticancer Res."},{"key":"1148_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1060098","volume":"12","author":"CL Tseng","year":"2022","unstructured":"Tseng, C. L. et al. High grade glioma radiation therapy on a high field 1.5 Tesla MR-Linac \u2014 workflow and initial experience with daily adapt-to-position (ATP) MR guidance: a first report. Front. Oncol. 12, 1060098 (2022).","journal-title":"Front. Oncol."},{"key":"1148_CR154","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s11060-022-04112-6","volume":"161","author":"O Bin-Alamer","year":"2023","unstructured":"Bin-Alamer, O. et al. Single session versus multisession stereotactic radiosurgery for the management of intracranial meningiomas: a systematic review and meta-analysis. J. Neurooncol. 161, 215\u2013224 (2023).","journal-title":"J. Neurooncol."},{"key":"1148_CR155","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/neuros\/nyy009","volume":"83","author":"CC Lee","year":"2018","unstructured":"Lee, C. C. et al. Stereotactic radiosurgery for benign (World Health Organization grade I) cavernous sinus meningiomas \u2014 International Stereotactic Radiosurgery Society (ISRS) Practice Guideline: a systematic review. Neurosurgery 83, 1128\u20131142 (2018).","journal-title":"Neurosurgery"},{"key":"1148_CR156","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/neuros\/nyaa169","volume":"87","author":"M Marchetti","year":"2020","unstructured":"Marchetti, M. et al. Stereotactic radiosurgery for intracranial noncavernous sinus benign meningioma: International Stereotactic Radiosurgery Society systematic review, meta-analysis and practice guideline. Neurosurgery 87, 879\u2013890 (2020).","journal-title":"Neurosurgery"},{"key":"1148_CR157","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ijrobp.2022.08.064","volume":"115","author":"V Pinzi","year":"2023","unstructured":"Pinzi, V. et al. Hypofractionated radiosurgery for large or in critical-site intracranial meningioma: results of a phase 2 prospective study. Int. J. Radiat. Oncol. Biol. Phys. 115, 153\u2013163 (2023).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1148_CR158","doi-asserted-by":"publisher","first-page":"e672","DOI":"10.1016\/j.ijrobp.2020.07.2007","volume":"108","author":"A Van Buren","year":"2020","unstructured":"Van Buren, A. et al. Local control and toxicity following hypofractionated stereotactic radiotherapy for intracranial meningioma. Int. J. Radiat. Oncol. Biol. Phys. 108, e672\u2013e673 (2020).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1148_CR159","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.3390\/curroncol28050314","volume":"28","author":"EK Nguyen","year":"2021","unstructured":"Nguyen, E. K., Pond, G. R., Greenspoon, J. N., Whitton, A. C. & Hann, C. Hypofractionated stereotactic radiotherapy for the treatment of benign intracranial meningiomas: long-term safety and efficacy. Curr. Oncol. 28, 3683\u20133691 (2021).","journal-title":"Curr. Oncol."},{"key":"1148_CR160","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172750","volume":"17","author":"Y Mizutani","year":"2025","unstructured":"Mizutani, Y. et al. Stereotactic radiosurgery for recurrent meningioma: a systematic review of risk factors and management approaches. Cancers 17, 2750 (2025).","journal-title":"Cancers"},{"key":"1148_CR161","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3109\/0284186X.2013.762996","volume":"52","author":"SE Combs","year":"2013","unstructured":"Combs, S. E. et al. Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and 68Ga-DOTATOC-PET. Acta Oncol. 52, 514\u2013520 (2013).","journal-title":"Acta Oncol."},{"key":"1148_CR162","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ijrobp.2005.12.006","volume":"65","author":"S Milker-Zabel","year":"2006","unstructured":"Milker-Zabel, S. et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int. J. Radiat. Oncol. Biol. Phys. 65, 222\u2013227 (2006).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1148_CR163","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1158\/1078-0432.CCR-20-3362","volume":"27","author":"A Bashir","year":"2021","unstructured":"Bashir, A., Larsen, V. A., Ziebell, M., Fugleholm, K. & Law, I. Improved detection of postoperative residual meningioma with [68Ga]Ga-DOTA-TOC PET imaging using a high-resolution research tomograph PET scanner. Clin. Cancer Res. 27, 2216\u20132225 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1148_CR164","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/neuonc\/noac137","volume":"25","author":"CL Rogers","year":"2023","unstructured":"Rogers, C. L. et al. Low-risk meningioma: initial outcomes from NRG Oncology\/RTOG 0539. Neuro Oncol. 25, 137\u2013145 (2023).","journal-title":"Neuro Oncol."},{"key":"1148_CR165","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1159\/000506902","volume":"110","author":"L Albano","year":"2020","unstructured":"Albano, L., Losa, M., Flickinger, J., Mortini, P. & Minniti, G. Radiotherapy of parasellar tumours. Neuroendocrinology 110, 848\u2013858 (2020).","journal-title":"Neuroendocrinology"},{"key":"1148_CR166","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller, M. et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat. Rev. Clin. Oncol. 18, 170\u2013186 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1148_CR167","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1016\/S1470-2045(16)30321-7","volume":"17","author":"R Goldbrunner","year":"2016","unstructured":"Goldbrunner, R. et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 17, e383\u2013e391 (2016).","journal-title":"Lancet Oncol."},{"key":"1148_CR168","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/BF00172765","volume":"13","author":"R Miralbell","year":"1992","unstructured":"Miralbell, R. et al. The role of radiotherapy in the treatment of subtotally resected benign meningiomas. J. Neurooncol. 13, 157\u2013164 (1992).","journal-title":"J. Neurooncol."},{"key":"1148_CR169","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-6-36","volume":"6","author":"G Minniti","year":"2011","unstructured":"Minniti, G. et al. Fractionated stereotactic conformal radiotherapy for large benign skull base meningiomas. Radiat. Oncol. 6, 36 (2011).","journal-title":"Radiat. Oncol."},{"key":"1148_CR170","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1200\/JCO.2001.19.15.3547","volume":"19","author":"J Debus","year":"2001","unstructured":"Debus, J. et al. High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results. J. Clin. Oncol. 19, 3547\u20133553 (2001).","journal-title":"J. Clin. Oncol."},{"key":"1148_CR171","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.radonc.2013.10.006","volume":"109","author":"F Sold\u00e0","year":"2013","unstructured":"Sold\u00e0, F. et al. Long-term efficacy of fractionated radiotherapy for benign meningiomas. Radiother. Oncol. 109, 330\u2013334 (2013).","journal-title":"Radiother. Oncol."},{"key":"1148_CR172","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1080\/0284186X.2022.2116994","volume":"61","author":"C Wujanto","year":"2022","unstructured":"Wujanto, C., Chan, T. Y., Soon, Y. Y. & Vellayappan, B. Should adjuvant radiotherapy be used in atypical meningioma (WHO grade 2) following gross total resection? A systematic review and meta-analysis. Acta Oncol. 61, 1075\u20131083 (2022).","journal-title":"Acta Oncol."},{"key":"1148_CR173","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.ijrobp.2013.12.037","volume":"88","author":"RH Press","year":"2014","unstructured":"Press, R. H. et al. Outcomes and patterns of failure for grade 2 meningioma treated with reduced-margin intensity modulated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 88, 1004\u20131010 (2014).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1148_CR174","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11060-019-03232-w","volume":"144","author":"JJB Lee","year":"2019","unstructured":"Lee, J. J. B. et al. Analysis of patterns of failure and appraisal of postoperative radiation field for grade II-III meningioma. J. Neurooncol. 144, 333\u2013341 (2019).","journal-title":"J. Neurooncol."},{"key":"1148_CR175","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ijrobp.2023.09.026","volume":"118","author":"KL Zeng","year":"2024","unstructured":"Zeng, K. L. et al. Dose-escalated radiation therapy is associated with improved outcomes for high-grade meningioma. Int. J. Radiat. Oncol. Biol. Phys. 118, 662\u2013671 (2024).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1148_CR176","volume":"41","author":"JZ Wang","year":"2023","unstructured":"Wang, J. Z. et al. Outcomes and predictors of response to fractionated radiotherapy as primary treatment for intracranial meningiomas. Clin. Transl. Radiat. Oncol. 41, 100631 (2023).","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"1148_CR177","doi-asserted-by":"publisher","first-page":"e1117","DOI":"10.1016\/j.wneu.2023.04.075","volume":"175","author":"M Palmieri","year":"2023","unstructured":"Palmieri, M. et al. Clinical efficacy of adjuvant radiotherapy for World Health Organization grade II intracranial meningioma. World Neurosurg. 175, e1117\u2013e1123 (2023).","journal-title":"World Neurosurg."},{"key":"1148_CR178","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-021-01759-9","volume":"16","author":"SW Chun","year":"2021","unstructured":"Chun, S. W. et al. Adjuvant radiotherapy versus observation following gross total resection for atypical meningioma: a systematic review and meta-analysis. Radiat. Oncol. 16, 34 (2021).","journal-title":"Radiat. Oncol."},{"key":"1148_CR179","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.11.028","volume":"106","author":"CL Rogers","year":"2020","unstructured":"Rogers, C. L. et al. High-risk Meningioma: initial outcomes from NRG Oncology\/RTOG 0539. Int. J. Radiat. Oncol. Biol. Phys. 106, 790\u2013799 (2020).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1148_CR180","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.radonc.2018.06.018","volume":"128","author":"DC Weber","year":"2018","unstructured":"Weber, D. C. et al. Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: a phase-II parallel non-randomized and observation study (EORTC 22042-26042). Radiother. Oncol. 128, 260\u2013265 (2018).","journal-title":"Radiother. Oncol."},{"key":"1148_CR181","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1093\/neuonc\/nou149","volume":"16","author":"MD Jenkinson","year":"2014","unstructured":"Jenkinson, M. D. et al. Radiotherapy versus observation following surgical resection of atypical meningioma (the ROAM trial). Neuro Oncol. 16, 1560\u20131561 (2014).","journal-title":"Neuro Oncol."},{"key":"1148_CR182","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3171\/2016.11.JNS161170","volume":"129","author":"L Rogers","year":"2018","unstructured":"Rogers, L. et al. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J. Neurosurg. 129, 35\u201347 (2018).","journal-title":"J. Neurosurg."},{"key":"1148_CR183","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.3171\/2019.1.JNS181771","volume":"132","author":"CL Dalle Ore","year":"2020","unstructured":"Dalle Ore, C. L. et al. Meningioma metastases: incidence and proposed screening paradigm. J. Neurosurg. 132, 1447\u20131455 (2020).","journal-title":"J. Neurosurg."},{"key":"1148_CR184","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1227\/01.NEU.0000170980.47582.A5","volume":"57","author":"A Modha","year":"2005","unstructured":"Modha, A. & Gutin, P. H. Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 57, 538\u2013550 (2005).","journal-title":"Neurosurgery"},{"key":"1148_CR185","first-page":"437","volume":"71","author":"K Wang","year":"2021","unstructured":"Wang, K. & Tepper, J. E. Radiation therapy-associated toxicity: etiology, management, and prevention. CA Cancer J. Clin. 71, 437\u2013454 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"1148_CR186","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0360-3016(02)03809-9","volume":"55","author":"A Pirzkall","year":"2003","unstructured":"Pirzkall, A. et al. Intensity modulated radiotherapy (IMRT) for recurrent, residual, or untreated skull-base meningiomas: preliminary clinical experience. Int. J. Radiat. Oncol. Biol. Phys. 55, 362\u2013372 (2003).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1148_CR187","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1200\/JCO.2011.38.6938","volume":"30","author":"LB Kenney","year":"2012","unstructured":"Kenney, L. B. et al. Male reproductive health after childhood, adolescent, and young adult cancers: a report from the Children\u2019s Oncology Group. J. Clin. Oncol. 30, 3408\u20133416 (2012).","journal-title":"J. Clin. Oncol."},{"key":"1148_CR188","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1200\/JCO.2008.21.1839","volume":"27","author":"DM Green","year":"2009","unstructured":"Green, D. M. et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J. Clin. Oncol. 27, 2374\u20132381 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1148_CR189","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1200\/JCO.2018.78.1492","volume":"36","author":"RE Vatner","year":"2018","unstructured":"Vatner, R. E. et al. Endocrine deficiency as a function of radiation dose to the hypothalamus and pituitary in pediatric and young adult patients with brain tumors. J. Clin. Oncol. 36, 2854\u20132862 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1148_CR190","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081846","volume":"13","author":"R Gondar","year":"2021","unstructured":"Gondar, R., Patet, G., Schaller, K. & Meling, T. R. Meningiomas and cognitive Impairment after treatment: a systematic and narrative review. Cancers 13, 1846 (2021).","journal-title":"Cancers"},{"key":"1148_CR191","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3109\/0284186X.2013.818255","volume":"52","author":"SE Combs","year":"2013","unstructured":"Combs, S. E. et al. Proton and carbon ion radiotherapy for primary brain tumors and tumors of the skull base. Acta Oncol. 52, 1504\u20131509 (2013).","journal-title":"Acta Oncol."},{"key":"1148_CR192","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.558845","volume":"10","author":"DC Weber","year":"2020","unstructured":"Weber, D. C., Bizzocchi, N., Bolsi, A. & Jenkinson, M. D. Proton therapy for intracranial meningioma for the treatment of primary\/recurrent disease including re-irradiation. Front. Oncol. 10, 558845 (2020).","journal-title":"Front. Oncol."},{"key":"1148_CR193","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ijrobp.2013.04.030","volume":"87","author":"CS Chung","year":"2013","unstructured":"Chung, C. S. et al. Incidence of second malignancies among patients treated with proton versus photon radiation. Int. J. Radiat. Oncol. Biol. Phys. 87, 46\u201352 (2013).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1148_CR194","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ijrobp.2005.01.057","volume":"63","author":"DC Weber","year":"2005","unstructured":"Weber, D. C. et al. Proton beam radiotherapy versus fractionated stereotactic radiotherapy for uveal melanomas: a comparative study. Int. J. Radiat. Oncol. Biol. Phys. 63, 373\u2013384 (2005).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1148_CR195","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7785\/tcrt.2012.500276","volume":"12","author":"ER Dennis","year":"2013","unstructured":"Dennis, E. R. et al. A comparison of critical structure dose and toxicity risks in patients with low grade gliomas treated with IMRT versus proton radiation therapy. Technol. Cancer Res. Treat. 12, 1\u20139 (2013).","journal-title":"Technol. Cancer Res. Treat."},{"key":"1148_CR196","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-018-1002-5","volume":"13","author":"RA El Shafie","year":"2018","unstructured":"El Shafie, R. A. et al. Clinical outcome after particle therapy for meningiomas of the skull base: toxicity and local control in patients treated with active rasterscanning. Radiat. Oncol. 13, 54 (2018).","journal-title":"Radiat. Oncol."},{"key":"1148_CR197","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.ijrobp.2017.08.005","volume":"99","author":"FR Murray","year":"2017","unstructured":"Murray, F. R. et al. Long-term clinical outcomes of pencil beam scanning proton therapy for benign and non-benign intracranial meningiomas. Int. J. Radiat. Oncol. Biol. Phys. 99, 1190\u20131198 (2017).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1148_CR198","doi-asserted-by":"publisher","DOI":"10.25259\/SNI_485_2023","volume":"15","author":"TA Wilson","year":"2024","unstructured":"Wilson, T. A. et al. Adjuvant proton beam therapy in patients with grade 2 meningiomas. Surg. Neurol. Int. 15, 62 (2024).","journal-title":"Surg. Neurol. Int."},{"key":"1148_CR199","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1227\/00006123-198706000-00020","volume":"20","author":"PH Gutin","year":"1987","unstructured":"Gutin, P. H. et al. Brachytherapy of recurrent tumors of the skull base and spine with iodine-125 sources. Neurosurgery 20, 938\u2013945 (1987).","journal-title":"Neurosurgery"},{"key":"1148_CR200","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/B978-0-12-822198-3.00049-5","volume":"170","author":"ST Magill","year":"2020","unstructured":"Magill, S. T., Schwartz, T. H., Theodosopoulos, P. V. & McDermott, M. W. Brachytherapy for meningiomas. Handb. Clin. Neurol. 170, 303\u2013307 (2020).","journal-title":"Handb. Clin. Neurol."},{"key":"1148_CR201","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1227\/01.NEU.0000097199.26412.2A","volume":"54","author":"ML Ware","year":"2004","unstructured":"Ware, M. L., Larson, D. A., Sneed, P. K., Wara, W. W. & McDermott, M. W. Surgical resection and permanent brachytherapy for recurrent atypical and malignant meningioma. Neurosurgery 54, 55\u201363 (2004).","journal-title":"Neurosurgery"},{"key":"1148_CR202","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3171\/2021.10.JNS211886","volume":"137","author":"WC Chen","year":"2022","unstructured":"Chen, W. C. et al. Resection with intraoperative cesium-131 brachytherapy as salvage therapy for recurrent brain tumors. J. Neurosurg. 137, 924\u2013930 (2022).","journal-title":"J. Neurosurg."},{"key":"1148_CR203","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194736","volume":"13","author":"J Kerschbaumer","year":"2021","unstructured":"Kerschbaumer, J. et al. Risk factors for radiation necrosis in patients undergoing cranial stereotactic radiosurgery. Cancers 13, 4736 (2021).","journal-title":"Cancers"},{"key":"1148_CR204","doi-asserted-by":"publisher","first-page":"E910","DOI":"10.1093\/neuros\/nyz115","volume":"85","author":"MJ Koch","year":"2019","unstructured":"Koch, M. J. et al. Brachytherapy as an adjuvant for recurrent atypical and malignant meningiomas. Neurosurgery 85, E910\u2013E916 (2019).","journal-title":"Neurosurgery"},{"key":"1148_CR205","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.3171\/2018.7.JNS18656","volume":"131","author":"DG Brachman","year":"2019","unstructured":"Brachman, D. G. et al. Resection and permanent intracranial brachytherapy using modular, biocompatible cesium-131 implants: results in 20 recurrent, previously irradiated meningiomas. J. Neurosurg. 131, 1819\u20131828 (2019).","journal-title":"J. Neurosurg."},{"key":"1148_CR206","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1002\/cncr.35279","volume":"130","author":"AL Hsieh","year":"2024","unstructured":"Hsieh, A. L., Bi, W. L., Ramesh, V., Brastianos, P. K. & Plotkin, S. R. Evolving concepts in meningioma management in the era of genomics. Cancer 130, 2586\u20132600 (2024).","journal-title":"Cancer"},{"key":"1148_CR207","doi-asserted-by":"publisher","DOI":"10.21037\/cco-20-226","volume":"10","author":"L Bender","year":"2021","unstructured":"Bender, L. et al. High risk of recurrence for grade II meningioma: a 10-year multicenter analysis of prognosis factors. Chin. Clin. Oncol. 10, 26 (2021).","journal-title":"Chin. Clin. Oncol."},{"key":"1148_CR208","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00401-023-02642-5","volume":"146","author":"SLN Maas","year":"2023","unstructured":"Maas, S. L. N. et al. Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042-26042. Acta Neuropathol. 146, 837\u2013840 (2023).","journal-title":"Acta Neuropathol."},{"key":"1148_CR209","doi-asserted-by":"publisher","first-page":"i18","DOI":"10.1093\/neuonc\/noy136","volume":"21","author":"PK Brastianos","year":"2019","unstructured":"Brastianos, P. K. et al. Advances in multidisciplinary therapy for meningiomas. Neuro Oncol. 21, i18\u2013i31 (2019).","journal-title":"Neuro Oncol."},{"key":"1148_CR210","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/neuonc\/noab243","volume":"24","author":"M Preusser","year":"2022","unstructured":"Preusser, M. et al. Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro Oncol. 24, 755\u2013767 (2022).","journal-title":"Neuro Oncol."},{"key":"1148_CR211","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s00280-014-2422-z","volume":"73","author":"M Simo","year":"2014","unstructured":"Simo, M. et al. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy. Cancer Chemother. Pharmacol. 73, 919\u2013923 (2014).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1148_CR212","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/267831","volume":"2015","author":"G Cossu","year":"2015","unstructured":"Cossu, G., Levivier, M., Daniel, R. T. & Messerer, M. The role of mifepristone in meningiomas management: a systematic review of the literature. Biomed. Res. Int. 2015, 267831 (2015).","journal-title":"Biomed. Res. Int."},{"key":"1148_CR213","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1093\/neuonc\/noaf009","volume":"27","author":"R Kotecha","year":"2025","unstructured":"Kotecha, R. et al. Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: a RANO group systematic review and meta-analysis to guide clinical trial design. Neuro Oncol. 27, 1670\u20131685 (2025).","journal-title":"Neuro Oncol."},{"key":"1148_CR214","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/WCO.0000000000000615","volume":"31","author":"VA Venur","year":"2018","unstructured":"Venur, V. A., Santagata, S., Galanis, E. & Brastianos, P. K. New molecular targets in meningiomas: the present and the future. Curr. Opin. Neurol. 31, 740\u2013746 (2018).","journal-title":"Curr. Opin. Neurol."},{"key":"1148_CR215","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11060-016-2172-3","volume":"129","author":"KC Shih","year":"2016","unstructured":"Shih, K. C. et al. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J. Neurooncol. 129, 281\u2013288 (2016).","journal-title":"J. Neurooncol."},{"key":"1148_CR216","volume":"4","author":"P Kumthekar","year":"2022","unstructured":"Kumthekar, P. et al. A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma. Neurooncol. Adv. 4, vdac123 (2022).","journal-title":"Neurooncol. Adv."},{"key":"1148_CR217","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11060-012-0886-4","volume":"109","author":"L Nayak","year":"2012","unstructured":"Nayak, L. et al. Atypical and anaplastic meningiomas treated with bevacizumab. J. Neurooncol. 109, 187\u2013193 (2012).","journal-title":"J. Neurooncol."},{"key":"1148_CR218","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/neuonc\/nou148","volume":"17","author":"TJ Kaley","year":"2015","unstructured":"Kaley, T. J. et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 17, 116\u2013121 (2015).","journal-title":"Neuro Oncol."},{"key":"1148_CR219","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1158\/1535-7163.MCT-21-0143","volume":"20","author":"MA Karajannis","year":"2021","unstructured":"Karajannis, M. A. et al. Phase 0 clinical trial of everolimus in patients with vestibular schwannoma or meningioma. Mol. Cancer Ther. 20, 1584\u20131591 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"1148_CR220","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1093\/neuonc\/nor044","volume":"13","author":"DR Johnson","year":"2011","unstructured":"Johnson, D. R. et al. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol. 13, 530\u2013535 (2011).","journal-title":"Neuro Oncol."},{"key":"1148_CR221","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","volume":"26","author":"T Graillon","year":"2020","unstructured":"Graillon, T. et al. Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial. Clin. Cancer Res. 26, 552\u2013557 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1148_CR222","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.4161\/cc.10.15.16776","volume":"10","author":"AK Witkiewicz","year":"2011","unstructured":"Witkiewicz, A. K., Knudsen, K. E., Dicker, A. P. & Knudsen, E. S. The meaning of p16ink4a expression in tumors: functional significance, clinical associations and future developments. Cell Cycle 10, 2497\u20132503 (2011).","journal-title":"Cell Cycle"},{"key":"1148_CR223","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1093\/neuonc\/noaf184","volume":"27","author":"TJ Kaley","year":"2025","unstructured":"Kaley, T. J. et al. Multicenter basket trial for central nervous system tumors identifies activity of the CDK4\/6 inhibitor abemaciclib in recurrent meningioma. Neuro Oncol. 27, 3189\u20133199 (2025).","journal-title":"Neuro Oncol."},{"key":"1148_CR224","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41591-025-04141-4","volume":"32","author":"PK Brastianos","year":"2026","unstructured":"Brastianos, P. K. et al. Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial. Nat. Med. 32, 717\u2013724 (2026).","journal-title":"Nat. Med."},{"key":"1148_CR225","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/neuonc\/noab118","volume":"24","author":"WL Bi","year":"2022","unstructured":"Bi, W. L. et al. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical\/anaplastic meningioma: phase II trial results. Neuro Oncol. 24, 101\u2013113 (2022).","journal-title":"Neuro Oncol."},{"key":"1148_CR226","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.18632\/oncotarget.3082","volume":"6","author":"Z Du","year":"2015","unstructured":"Du, Z. et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget 6, 4704\u20134716 (2015).","journal-title":"Oncotarget"},{"key":"1148_CR227","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/14737140.2024.2399252","volume":"24","author":"AJ White","year":"2024","unstructured":"White, A. J., Harary, M., Casaos, J. & Everson, R. G. Current immunotherapy techniques in meningioma. Expert. Rev. Anticancer. Ther. 24, 931\u2013941 (2024).","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"1148_CR228","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29052-7","volume":"13","author":"PK Brastianos","year":"2022","unstructured":"Brastianos, P. K. et al. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat. Commun. 13, 1325 (2022).","journal-title":"Nat. Commun."},{"key":"1148_CR229","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1093\/neuonc\/noaf155","volume":"27","author":"R Ramapriyan","year":"2025","unstructured":"Ramapriyan, R. et al. Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells. Neuro Oncol. 27, 3104\u20133118 (2025).","journal-title":"Neuro Oncol."},{"key":"1148_CR230","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s11060-025-05200-z","volume":"175","author":"MZ Sun","year":"2025","unstructured":"Sun, M. Z. et al. Immunotherapeutic targeting of NY-ESO-1 in malignant meningiomas with TCR-transduced T-cells. J. Neurooncol. 175, 1079\u20131089 (2025).","journal-title":"J. Neurooncol."},{"key":"1148_CR231","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/j.wneu.2019.10.044","volume":"135","author":"J Deng","year":"2020","unstructured":"Deng, J. et al. Expression and clinical significance of immune checkpoint regulator B7-H3 (CD276) in human meningioma. World Neurosurg. 135, e12\u2013e18 (2020).","journal-title":"World Neurosurg."},{"key":"1148_CR232","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1512943","volume":"8","author":"DT Proctor","year":"2019","unstructured":"Proctor, D. T. et al. Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma. Oncoimmunology 8, e1512943 (2019).","journal-title":"Oncoimmunology"},{"key":"1148_CR233","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1200\/JCO.21.02371","volume":"41","author":"PK Brastianos","year":"2023","unstructured":"Brastianos, P. K. et al. Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations. J. Clin. Oncol. 41, 618\u2013628 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1148_CR234","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1097\/CM9.0000000000003713","volume":"138","author":"L Zhou","year":"2025","unstructured":"Zhou, L. et al. Boron neutron capture therapy: a new era in radiotherapy. Chin. Med. J. 138, 2517\u20132519 (2025).","journal-title":"Chin. Med. J."},{"key":"1148_CR235","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1039\/D0CC06557A","volume":"57","author":"M Lamba","year":"2021","unstructured":"Lamba, M., Goswami, A. & Bandyopadhyay, A. A periodic development of BPA and BSH based derivatives in boron neutron capture therapy (BNCT). Chem. Commun. 57, 827\u2013839 (2021).","journal-title":"Chem. Commun."},{"key":"1148_CR236","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7150\/thno.123376","volume":"16","author":"W Wang","year":"2026","unstructured":"Wang, W. et al. State-of-the-art boron clusters for boron neutron-capture therapy. Theranostics 16, 417\u2013464 (2026).","journal-title":"Theranostics"},{"key":"1148_CR237","first-page":"ZE01","volume":"10","author":"K Nedunchezhian","year":"2016","unstructured":"Nedunchezhian, K., Aswath, N., Thiruppathy, M. & Thirugnanamurthy, S. Boron neutron capture therapy \u2014 a literature review. J. Clin. Diagn. Res. 10, ZE01\u2013ZE04 (2016).","journal-title":"J. Clin. Diagn. Res."},{"key":"1148_CR238","doi-asserted-by":"publisher","first-page":"S322","DOI":"10.1055\/s-0038-1666837","volume":"79","author":"K Takeuchi","year":"2018","unstructured":"Takeuchi, K. et al. Boron neutron capture therapy for high-grade skull-base meningioma. J. Neurol. Surg. B Skull Base 79, S322\u2013S327 (2018).","journal-title":"J. Neurol. Surg. B Skull Base"},{"key":"1148_CR239","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1227\/01.neu.0000279727.90650.24","volume":"61","author":"S Miyatake","year":"2007","unstructured":"Miyatake, S. et al. Boron neutron capture therapy for malignant tumors related to meningiomas. Neurosurgery 61, 82\u201390 (2007).","journal-title":"Neurosurgery"},{"key":"1148_CR240","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3171\/2013.5.JNS122204","volume":"119","author":"S Kawabata","year":"2013","unstructured":"Kawabata, S., Hiramatsu, R., Kuroiwa, T., Ono, K. & Miyatake, S. Boron neutron capture therapy for recurrent high-grade meningiomas. J. Neurosurg. 119, 837\u2013844 (2013).","journal-title":"J. Neurosurg."},{"key":"1148_CR241","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054978","volume":"24","author":"TL Lan","year":"2023","unstructured":"Lan, T. L. et al. Advances in boron neutron capture therapy (BNCT) for recurrent intracranial meningioma. Int. J. Mol. Sci. 24, 4978 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1148_CR242","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s11060-025-05184-w","volume":"175","author":"TL Lan","year":"2025","unstructured":"Lan, T. L. et al. Recurrent meningioma treated with boron neutron capture therapy: a feasibility study with dosimetric and clinical correlates. J. Neurooncol. 175, 879\u2013886 (2025).","journal-title":"J. Neurooncol."},{"key":"1148_CR243","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2967\/jnumed.123.266205","volume":"65","author":"N Tolboom","year":"2024","unstructured":"Tolboom, N. et al. Theranostics in neurooncology: heading toward new horizons. J. Nucl. Med. 65, 167\u2013173 (2024).","journal-title":"J. Nucl. Med."},{"key":"1148_CR244","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41591-022-01759-6","volume":"28","author":"C Arnold","year":"2022","unstructured":"Arnold, C. Theranostics could be big business in precision oncology. Nat. Med. 28, 606\u2013608 (2022).","journal-title":"Nat. Med."},{"key":"1148_CR245","doi-asserted-by":"publisher","first-page":"704","DOI":"10.2967\/jnumed.122.264586","volume":"64","author":"DL Bailey","year":"2023","unstructured":"Bailey, D. L. et al. 64Cu treatment planning and 67Cu therapy with radiolabeled [64Cu\/67Cu]MeCOSar-octreotate in subjects with unresectable multifocal meningioma: initial results for human imaging, safety, biodistribution, and radiation dosimetry. J. Nucl. Med. 64, 704\u2013710 (2023).","journal-title":"J. Nucl. Med."},{"key":"1148_CR246","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg, J. et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125\u2013135 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1148_CR247","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/RLU.0000000000005845","volume":"50","author":"J Zhang","year":"2025","unstructured":"Zhang, J. et al. Long-term efficacy, survival, and toxicity of peptide receptor radionuclide therapy in patients with refractory meningioma. Clin. Nucl. Med. 50, 508\u2013516 (2025).","journal-title":"Clin. Nucl. Med."},{"key":"1148_CR248","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00259-009-1115-z","volume":"36","author":"M Bartolomei","year":"2009","unstructured":"Bartolomei, M. et al. Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma. Eur. J. Nucl. Med. Mol. Imaging 36, 1407\u20131416 (2009).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1148_CR249","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2967\/jnumed.114.147256","volume":"56","author":"N Marincek","year":"2015","unstructured":"Marincek, N. et al. Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J. Nucl. Med. 56, 171\u2013176 (2015).","journal-title":"J. Nucl. Med."},{"key":"1148_CR250","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-23-2533","volume":"30","author":"SC Kurz","year":"2024","unstructured":"Kurz, S. C. et al. Evaluation of the SSTR2-targeted radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as imaging biomarker in patients with intracranial meningioma. Clin. Cancer Res. 30, 680\u2013686 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1148_CR251","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17122039","volume":"17","author":"B Muoio","year":"2025","unstructured":"Muoio, B. et al. Peptide receptor radionuclide therapy in patients with advanced, recurrent or progressive meningioma: an updated systematic review and meta-analysis. Cancers 17, 2039 (2025).","journal-title":"Cancers"},{"key":"1148_CR252","doi-asserted-by":"publisher","first-page":"217","DOI":"10.23736\/S1824-4785.24.03571-4","volume":"68","author":"C Boursier","year":"2024","unstructured":"Boursier, C., Zaragori, T., Imbert, L. & Verger, A. 177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review. Q. J. Nucl. Med. Mol. Imaging 68, 217\u2013225 (2024).","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"1148_CR253","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-7-99","volume":"7","author":"MC Kreissl","year":"2012","unstructured":"Kreissl, M. C. et al. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat. Oncol. 7, 99 (2012).","journal-title":"Radiat. Oncol."},{"key":"1148_CR254","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1093\/neuonc\/now188.059","volume":"18","author":"K Seystahl","year":"2016","unstructured":"Seystahl, K. et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE\/-TOC uptake. Neuro Oncol. 18, 1538\u20131547 (2016).","journal-title":"Neuro Oncol."},{"key":"1148_CR255","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1055\/a-0802-5039","volume":"58","author":"FA Verburg","year":"2019","unstructured":"Verburg, F. A., Wiessmann, M., Neuloh, G., Mottaghy, F. M. & Brockmann, M. A. Intraindividual comparison of selective intraarterial versus systemic intravenous 68Ga-DOTATATE PET\/CT in patients with inoperable meningioma. Nuklearmedizin 58, 23\u201327 (2019).","journal-title":"Nuklearmedizin"},{"key":"1148_CR256","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s00270-019-02262-1","volume":"42","author":"A Braat","year":"2019","unstructured":"Braat, A., Snijders, T. J., Seute, T. & Vonken, E. P. A. Will 177Lu-DOTATATE treatment become more effective in salvage meningioma patients, when boosting somatostatin receptor saturation? A promising case on intra-arterial administration. Cardiovasc. Intervent. Radiol. 42, 1649\u20131652 (2019).","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"1148_CR257","first-page":"1911","volume":"65","author":"A Amerein","year":"2024","unstructured":"Amerein, A. et al. Intraarterial administration of peptide receptor radionuclide therapy in patients with advanced meningioma: initial safety and efficacy. J. Nucl. Med. 65, 1911\u20131916 (2024).","journal-title":"J. Nucl. Med."},{"key":"1148_CR258","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2967\/jnumed.121.262491","volume":"63","author":"EPA Vonken","year":"2022","unstructured":"Vonken, E. P. A. et al. Intraarterial administration boosts 177Lu-HA-DOTATATE accumulation in salvage meningioma patients. J. Nucl. Med. 63, 406\u2013409 (2022).","journal-title":"J. Nucl. Med."},{"key":"1148_CR259","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s00259-025-07336-6","volume":"53","author":"N Hasenauer","year":"2025","unstructured":"Hasenauer, N. et al. SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors. Eur. J. Nucl. Med. Mol. Imaging 53, 116\u2013127 (2025).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1148_CR260","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2967\/jnumed.125.269633","volume":"67","author":"NL Albert","year":"2025","unstructured":"Albert, N. L. et al. [177Lu]Lu-DOTATATE for recurrent meningioma (LUMEN-1, EORTC-2334-BTG): study protocol for a randomized phase II trial. J. Nucl. Med. 67, 23\u201330 (2025).","journal-title":"J. Nucl. Med."},{"key":"1148_CR261","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11060-022-04171-9","volume":"160","author":"WC Chen","year":"2022","unstructured":"Chen, W. C. et al. Radiotherapy for meningiomas. J. Neurooncol. 160, 505\u2013515 (2022).","journal-title":"J. Neurooncol."},{"key":"1148_CR262","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-4-42","volume":"4","author":"G Minniti","year":"2009","unstructured":"Minniti, G., Amichetti, M. & Enrici, R. M. Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat. Oncol. 4, 42 (2009).","journal-title":"Radiat. Oncol."},{"key":"1148_CR263","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.radonc.2014.04.003","volume":"111","author":"E Fokas","year":"2014","unstructured":"Fokas, E., Henzel, M., Surber, G., Hamm, K. & Engenhart-Cabillic, R. Stereotactic radiotherapy of benign meningioma in the elderly: clinical outcome and toxicity in 121 patients. Radiother. Oncol. 111, 457\u2013462 (2014).","journal-title":"Radiother. Oncol."},{"key":"1148_CR264","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1227\/NEU.0000000000000633","volume":"76","author":"A Mansouri","year":"2015","unstructured":"Mansouri, A. et al. Stereotactic radiosurgery for intracranial meningiomas: current concepts and future perspectives. Neurosurgery 76, 362\u2013371 (2015).","journal-title":"Neurosurgery"},{"key":"1148_CR265","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2025.103877","volume":"44","author":"G Singh","year":"2025","unstructured":"Singh, G. et al. Effectiveness of intensity modulate proton therapy in managing complex multiple meningiomas: a dosimetric and radiobiological comparative study with helical tomotherapy on neurological risk. Clin. Oncol. 44, 103877 (2025).","journal-title":"Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01148-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01148-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01148-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:01:36Z","timestamp":1782302496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01148-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":265,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1148"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01148-9","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"26 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.S. is a co-founder and shareholder of Heidelberg Epignostix, and receives royalties for intellectual property in the field of diagnostics and honoraria from Illumina, Ipsen, Medsir and Servier. J.I. receives funding from Curium and GE Healthcare (both as principal investigator in investigator-initiated trial grants). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}